AIMC Topic: Neoplasm Grading

Clear Filters Showing 1 to 10 of 389 articles

Exploring the feasibility of AI-based analysis of histopathological variability in salivary gland tumours.

Scientific reports
This study uses artificial intelligence (AI) for differentiation between salivary gland tumours (SGT) using digitised Haematoxylin and Eosin stained whole-slide images (WSI). Machine learning (ML) classifiers were developed and tested using 320 scann...

Artificial intelligence algorithms for differentiating pseudoprogression from true progression in high-grade gliomas: A systematic review and meta-analysis.

Neurosurgical review
Differentiating pseudoprogression (PsP) from true progression (TP) in high-grade glioma (HGG) patients is still challenging and critical for effective treatment management. This meta-analysis evaluates the diagnostic accuracy of artificial intelligen...

Machine learning of whole-brain resting-state fMRI signatures for individualized grading of frontal gliomas.

Cancer imaging : the official publication of the International Cancer Imaging Society
PURPOSE: Accurate preoperative grading of gliomas is critical for therapeutic planning and prognostic evaluation. We developed a noninvasive machine learning model leveraging whole-brain resting-state functional magnetic resonance imaging (rs-fMRI) b...

Comparison of performance of cervical cancer grading based on acetowhite areas.

Scientific reports
Cervical cancer ranks fourth globally in terms of both incidence and mortality among women, making timely diagnosis essential for effective treatment. Although the acetowhite regions and their margins are important for cervical cancer staging, their ...

Histopathological-based brain tumor grading using 2D-3D multi-modal CNN-transformer combined with stacking classifiers.

Scientific reports
Reliability in diagnosing and treating brain tumors depends on the accurate grading of histopathological images. However, limited scalability, adaptability, and interpretability challenge current methods for frequently grading brain tumors to accurat...

Unveiling key pathomic features for automated diagnosis and Gleason grade estimation in prostate cancer.

BMC medical imaging
BACKGROUND: Recent advances in histology scanning technology and Artificial Intelligence (AI) offer great opportunities to support cancer diagnosis. The inability to interpret the extracted features and model predictions is one of the major issues li...

A radiomics-based interpretable model integrating delayed-phase CT and clinical features for predicting the pathological grade of appendiceal pseudomyxoma peritonei.

BMC medical imaging
OBJECTIVE: This study aimed to develop an interpretable machine learning model integrating delayed-phase contrast-enhanced CT radiomics with clinical features for noninvasive prediction of pathological grading in appendiceal pseudomyxoma peritonei (P...

Predicting the molecular subtypes of 2021 WHO grade 4 glioma by a multiparametric MRI-based machine learning model.

BMC cancer
BACKGROUND: Accurately distinguishing the different molecular subtypes of 2021 World Health Organization (WHO) grade 4 Central Nervous System (CNS) gliomas is highly relevant for prognostic stratification and personalized treatment.

Development and retrospective validation of an artificial intelligence system for diagnostic assessment of prostate biopsies: study protocol.

BMJ open
INTRODUCTION: Histopathological evaluation of prostate biopsies using the Gleason scoring system is critical for prostate cancer diagnosis and treatment selection. However, grading variability among pathologists can lead to inconsistent assessments, ...

Intralesional and perilesional radiomics strategy based on different machine learning for the prediction of international society of urological pathology grade group in prostate cancer.

BMC medical imaging
OBJECTIVE: To develop and evaluate a intralesional and perilesional radiomics strategy based on different machine learning model to differentiate International Society of Urological Pathology (ISUP) grade > 2 group and ISUP ≤ 2 prostate cancers (PCa)...